Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Company Overview - Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of small molecule medicines using targeted protein degradation (TPD) [5] - The company aims to address critical health problems and improve patients' lives by deploying TPD to target disease pathways that are inaccessible with conventional therapeutics [5] - Kymera has advanced its first degrader into clinical trials for immunological diseases and is also developing oncology programs targeting undrugged or poorly drugged proteins [5] Recent Financial Activity - Kymera Therapeutics announced the closing of an upsized underwritten public offering totaling $225 million, which included common stock and pre-funded warrants [1] - The company sold 2,830,533 shares of common stock at a public offering price of$40.75 per share, along with pre-funded warrants to purchase 3,519,159 shares at a price of $40.7499 each [1] - The gross proceeds from the offering were approximately$258.75 million before deducting underwriting discounts and commissions [1] Underwriters and Regulatory Compliance - Morgan Stanley, J.P. Morgan, TD Cowen, and Stifel acted as joint book-running managers for the offering [2] - The securities were offered under an automatically effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) [3]